Identification of MEN1 loss-off function as a potential biomarker for immune checkpoint therapy
type: CreativeWork
description: Immune-based therapies are an emerging field in the treatment of cancers, with immune checkpoint inhibitor therapies proving to be particularly effective, even in typically hard to treat cancers. Despite effective immune checkpoint therapies now being available, it is still difficult to predict response to treatment and therefore stratify patient care. Blockade of PD- 1/PD-L1 (Programmed death receptor (ligand) 1) has shown potent antitumor activity but therapies are limited by a lack of patient stratification. It was hypothesised that loss of tumour suppressor genes (TSGs), not previously known to induce immunogenicity, could upregulate PD-L1 expression, and if this occurred alongside an increase in tumour immunogenicity as measured by increased cytokine expression these genes could represent additional diseases amenable to immune checkpoint therapy. It was found that loss of MEN1 led to increased PD-L1 expression, as well as upregulated expression of the cytokines CXCL10 and CCL5. MEN1 is a TSG encoding the 68kDa protein menin, which has a range of poorly defined functions including an association with homologous-recombination (HR) DNA repair genes, specifically BRCA1, RAD51, and RAD51-AP1. Menin appears to regulate genes through transcriptional regulation but in some cases, such as the stabilisation of FANCD2, also via direct protein binding. MEN1 mutation predisposes to multiple endocrine neoplasia 1 syndrome, characterised by the development of a range of neuroendocrine tumours, and affected patients have limited treatment options. The biology underpinning MEN1 loss may lead to a tumour environment in the correct state to be targeted by immune checkpoint therapies, potentially in combination with a DNA damaging agent. Immune checkpoint therapies could provide a more effective option for universal treatment of tumours linked to MEN1 loss-of-function. Thesis embargoed until 31 December 2023.
abstract: Immune-based therapies are an emerging field in the treatment of cancers, with immune checkpoint inhibitor therapies proving to be particularly effective, even in typically hard to treat cancers. Despite effective immune checkpoint therapies now being available, it is still difficult to predict response to treatment and therefore stratify patient care. Blockade of PD- 1/PD-L1 (Programmed death receptor (ligand) 1) has shown potent antitumor activity but therapies are limited by a lack of patient stratification. It was hypothesised that loss of tumour suppressor genes (TSGs), not previously known to induce immunogenicity, could upregulate PD-L1 expression, and if this occurred alongside an increase in tumour immunogenicity as measured by increased cytokine expression these genes could represent additional diseases amenable to immune checkpoint therapy. It was found that loss of MEN1 led to increased PD-L1 expression, as well as upregulated expression of the cytokines CXCL10 and CCL5. MEN1 is a TSG encoding the 68kDa protein menin, which has a range of poorly defined functions including an association with homologous-recombination (HR) DNA repair genes, specifically BRCA1, RAD51, and RAD51-AP1. Menin appears to regulate genes through transcriptional regulation but in some cases, such as the stabilisation of FANCD2, also via direct protein binding. MEN1 mutation predisposes to multiple endocrine neoplasia 1 syndrome, characterised by the development of a range of neuroendocrine tumours, and affected patients have limited treatment options. The biology underpinning MEN1 loss may lead to a tumour environment in the correct state to be targeted by immune checkpoint therapies, potentially in combination with a DNA damaging agent. Immune checkpoint therapies could provide a more effective option for universal treatment of tumours linked to MEN1 loss-of-function. Thesis embargoed until 31 December 2023.
author: Thompson, Kyle
language: eng
date published: 2019-12
date modified: 2026-07-24T03:56:18Z
provider: Queen's University Belfast
publisher: Networked Digital Library of Theses and Dissertations
type: WebPage
source organization: Queen's University Belfast